Article

Identification of disease-specific diagnostic and prognostic biomarkers allowing
for an early characterization and accurate clinical follow-up of Alzheimer's
disease (AD) patients is a major clinical objective. Increasing evidences
implicate both humoral and cellular adaptive immune responses in the
pathophysiology of AD. Such disease-related B- and T-cell responses constitute a
promising source of potential specific early biomarkers. Among them, levels of
anti-Abeta antibodies in the serum and/or cerebrospinal fluid of patients may
correlate with AD progression, clinical presentation of the disease, and
occurrence of associated pathologies related to cerebral amyloid angiopathy. In
the same line, Abeta-specific T cell responses and immune regulatory populations
implicated in their modulation appear to play a role in the pathophysiology of AD
and cerebral amyloid angiopathy. Further characterization of both autoantibodies
and T cell responses specific for disease-related proteins, i.e. Abeta and
hyperphosphorylated Tau, will allow better deciphering their interest as early
diagnostic and prognostic markers in AD. Biomarkers of adaptive immune responses
specific for other pathological proteins may also apply to other neurological
disorders associated with abnormal protein deposition.
CI - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS